

In the Claims

Please amend claims 1, 10, 85, 86, 100 and 105. This listing of the claims will replace all prior versions, and listings, of claims in the application.

LISTING OF THE CLAIMS

1. (Currently Amended) A method of enhancing migration of calcium-sensing receptor expressing hematopoietic cells to a specific site in a subject, comprising:
locally administering to a specific site in a subject in need of such treatment a nonCa⁺⁺ calcium sensing receptor agonist in an amount effective to enhance migration of calcium-sensing receptor expressing hematopoietic cells to the specific site in the subject.
- 2-9. (Cancelled)
10. (Currently Amended) A method of inhibiting migration of calcium-sensing receptor expressing hematopoietic cells to a specific site in a subject, comprising:
locally administering to a specific site in a subject in need of such treatment a calcium-sensing receptor antagonist in an amount effective to inhibit migration of calcium-sensing receptor expressing hematopoietic cells to the specific site in the subject.
- 11-84. (Cancelled)
85. (Currently Amended) The method of claim 1, wherein the ~~calcium-sensing receptor expressing~~ hematopoietic cells are ~~monocytes~~ hematopoietic cells.
86. (Currently Amended) The method of claim 85, wherein the hematopoietic cells are hematopoietic progenitor cells.
87. (Cancelled)
88. (Cancelled)
89. (Cancelled)
90. (Cancelled)

91. (Previously Presented) The method of claim 1, wherein the nonCa⁺⁺ calcium-sensing receptor agonist is R-N-(3-methoxy- α -phenylethyl)-3-(2'-chlorophenyl)-1-propyl amine (NPS R-467) or salts thereof.
92. (Previously Presented) The method of claim 1, wherein the nonCa⁺⁺ calcium-sensing receptor agonist is (S)-N-(3-methoxy- α -phenylethyl)-3-(2'-chlorophenyl)-1-propyl amine (NPS s-467) or salts thereof.
93. (Previously Presented) The method of claim 10, wherein the specific site is a site of inflammation.
94. (Previously Presented) The method of claim 93, further comprising co-administering a non-calcium-sensing receptor antagonist that inhibits migration of immune cells to the site of inflammation in the subject.
95. (Previously Presented) The method of claim 94, wherein the non-calcium-sensing receptor antagonist is an antiinflammatory agent.
96. (Previously Presented) The method of claim 10, wherein the subject has an autoimmune disease.
97. (Previously Presented) The method of claim 96, wherein the autoimmune disease is rheumatoid arthritis, uveitis, insulin-dependent diabetes mellitus, hemolytic anemias, rheumatic fever, Crohn's disease, Guillain-Barre syndrome, psoriasis, thyroiditis, Graves' disease, myasthenia gravis, glomerulonephritis, autoimmune hepatitis, or systemic lupus erythematosus.
98. (Previously Presented) The method of claim 10, wherein the subject has an abscess, a transplant, an implant, atherosclerosis, or myocarditis.
99. (Cancelled)
100. (Currently Amended) The method of claim 9998, wherein the hematopoietic cells are hematopoietic progenitor cells.

101. (Cancelled)

102. (Cancelled)

103. (Cancelled)

104. (Cancelled)

105. (Currently Amended) The method according to any of claims 10 or 93-10498 and 100, wherein the calcium-sensing receptor antagonist is N-[(R)-2-hydroxy-3-(2-cyano-3-chlorophenoxy) propyl]-1-dimethyl-2-(2-napthyl) ethylamine (NPS 2143).